BACKGROUND: Radiofrequency ablation (RFA) is currently recommended for dysplastic Barrett's oesophagus (BO); however, there are limited data on treatment response when stratified by baseline histology. OBJECTIVE: The objective of this article is to evaluate RFA outcomes and durability for BO with different baseline histology. METHODS: Patients treated with RFA between 2007 and 2017 at a single institution were retrospectively included. Outcome measures were: (a) complete remission of dysplasia (CRD) and intestinal metaplasia (CRIM) at 18 months, (b) complication rate and (c) durability of CRD and CRIM. RESULTS: A total of 148 patients underwent RFA, of whom 113 completed the treatment protocol (21 low-grade dysplasia (LGD), 46 high-grade dysplasia (HGD) and 46 intramucosal carcinoma (IMC)). CRD and CRIM were achieved in 94.7% and 78.8% of patients, respectively. When stratified by baseline histology, there was no significant difference in CRD between groups (LGD, 95.2%; HGD, 95.7%; and IMC, 93.5%; p = 0.89). Similarly, there was no significant difference in CRIM between groups (LGD, 71.4%; HGD, 76.1% and IMC, 87.0%; p = 0.39). CRD and CRIM durability at 24 months for LGD, HGD and IMC were 100%, 97.7% and 100% (log rank p = 0.31), and 100%, 89.0% and 95.5%, respectively (log rank p = 0.62). CONCLUSION: Baseline histology is not a predictor of RFA response. Once CRD and CRIM are achieved, these effects are durable over time.
BACKGROUND: Radiofrequency ablation (RFA) is currently recommended for dysplastic Barrett's oesophagus (BO); however, there are limited data on treatment response when stratified by baseline histology. OBJECTIVE: The objective of this article is to evaluate RFA outcomes and durability for BO with different baseline histology. METHODS: Patients treated with RFA between 2007 and 2017 at a single institution were retrospectively included. Outcome measures were: (a) complete remission of dysplasia (CRD) and intestinal metaplasia (CRIM) at 18 months, (b) complication rate and (c) durability of CRD and CRIM. RESULTS: A total of 148 patients underwent RFA, of whom 113 completed the treatment protocol (21 low-grade dysplasia (LGD), 46 high-grade dysplasia (HGD) and 46 intramucosal carcinoma (IMC)). CRD and CRIM were achieved in 94.7% and 78.8% of patients, respectively. When stratified by baseline histology, there was no significant difference in CRD between groups (LGD, 95.2%; HGD, 95.7%; and IMC, 93.5%; p = 0.89). Similarly, there was no significant difference in CRIM between groups (LGD, 71.4%; HGD, 76.1% and IMC, 87.0%; p = 0.39). CRD and CRIM durability at 24 months for LGD, HGD and IMC were 100%, 97.7% and 100% (log rank p = 0.31), and 100%, 89.0% and 95.5%, respectively (log rank p = 0.62). CONCLUSION: Baseline histology is not a predictor of RFA response. Once CRD and CRIM are achieved, these effects are durable over time.
Authors: Rehan J Haidry; Gideon Lipman; Matthew R Banks; Mohammed A Butt; Vinay Sehgal; David Graham; Jason M Dunn; Abhinav Gupta; Rami Sweis; Haroon Miah; Danielle Morris; Howard L Smart; Pradeep Bhandari; Robert Willert; Grant Fullarton; Jonathon Morris; Massimo Di Pietro; Charles Gordon; Ian Penman; High Barr; Praful Patel; Philip Boger; Neil Kapoor; Brinder Mahon; Jonathon Hoare; Ravi Narayanasamy; Dermot O'Toole; Edward Cheong; Natalie C Direkze; Yeng Ang; Andrew Veitch; Anjan Dhar; David Nyalender; Krish Ragunath; Anthony Leahy; Mark Fullard; Manuel Rodriguez-Justo; Marco Novelli; Laurence B Lovat Journal: Endoscopy Date: 2015-06-30 Impact factor: 10.093
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Hannah T Künzli; Dirk W Schölvinck; K Nadine Phoa; Erik J Schoon; Martin H Houben; Jacques J G H M Bergman; Bas L A M Weusten Journal: Endoscopy Date: 2015-02-12 Impact factor: 10.093
Authors: Sarina Pasricha; William J Bulsiewicz; Kelly E Hathorn; Srinadh Komanduri; V Raman Muthusamy; Richard I Rothstein; Herbert C Wolfsen; Charles J Lightdale; Bergein F Overholt; Daniel S Camara; Evan S Dellon; William D Lyday; Atilla Ertan; Gary W Chmielewski; Nicholas J Shaheen Journal: Clin Gastroenterol Hepatol Date: 2014-05-09 Impact factor: 11.382
Authors: Frederike G I van Vilsteren; K Nadine Phoa; Lorenza Alvarez Herrero; Roos E Pouw; Carine M T Sondermeijer; Mike Visser; Fiebo J W Ten Kate; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Jacques J G H M Bergman Journal: Gastrointest Endosc Date: 2013-03-23 Impact factor: 9.427
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker Journal: Gut Date: 2013-10-28 Impact factor: 23.059
Authors: R J Haidry; M A Butt; J M Dunn; A Gupta; G Lipman; H L Smart; P Bhandari; L Smith; R Willert; G Fullarton; M Di Pietro; C Gordon; I Penman; H Barr; P Patel; N Kapoor; J Hoare; R Narayanasamy; Y Ang; A Veitch; K Ragunath; M Novelli; L B Lovat Journal: Gut Date: 2014-12-24 Impact factor: 23.059
Authors: Wei Keith Tan; Krish Ragunath; Jonathan R White; Jose Santiago; Jacobo Ortiz Fernandez-Sordo; Mirela Pana; Bincy Alias; Andreas V Hadjinicolaou; Vijay Sujendran; Massimiliano di Pietro Journal: Endosc Int Open Date: 2020-01-22